Topics:
Genitourinary Cancers • Prostate Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Johns Hopkins • NCI-CCC GU Tumor Board Question • Endocrinology
For high-volume metastatic CRPC to bone, what dosing schedule of zoledronic acid or denosumab do you use?
With the data primarily in breast cancer supporting q3 month zoledronate rather than monthly dosing, is this reasonable to do in mCRPC?